Is Jenburkt Pharma overvalued or undervalued?

As of 4 July 2025, the valuation grade for Jenburkt Pharma has moved from expensive to very expensive, indicating a significant shift in its perceived market value. The company is currently considered overvalued. Key ratios include a PE Ratio of 18.96, an EV to EBITDA of 14.49, and a ROCE of 23.71%.
When compared to peers, Jenburkt Pharma's valuation stands out, particularly against Sun Pharma, which has a PE Ratio of 35.2, and Cipla, which has a PE Ratio of 23.2. This suggests that while Jenburkt Pharma is performing well, it is priced higher relative to its earnings potential compared to some competitors. Notably, Jenburkt Pharma has outperformed the Sensex over various time frames, including a 1-year return of 56.85% compared to the Sensex's 4.23%, reinforcing the notion of its current overvaluation.